IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 278 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.58 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $288,415 | -22.9% | 63,388 | +19.4% | 0.00% | -33.3% |
| Q2 2023 | $373,866 | +78.4% | 53,106 | +54.8% | 0.00% | +50.0% |
| Q1 2023 | $209,579 | -1.8% | 34,301 | +2.7% | 0.00% | 0.0% |
| Q4 2022 | $213,394 | -30.5% | 33,395 | +4.3% | 0.00% | -33.3% |
| Q3 2022 | $307,000 | -13.0% | 32,033 | +0.3% | 0.00% | 0.0% |
| Q2 2022 | $353,000 | -37.5% | 31,945 | -5.9% | 0.00% | -40.0% |
| Q1 2022 | $565,000 | -11.3% | 33,930 | +1.6% | 0.01% | 0.0% |
| Q4 2021 | $637,000 | -22.4% | 33,381 | +0.2% | 0.01% | -28.6% |
| Q3 2021 | $821,000 | -1.3% | 33,308 | +4.2% | 0.01% | 0.0% |
| Q2 2021 | $832,000 | -17.9% | 31,962 | -0.2% | 0.01% | -22.2% |
| Q1 2021 | $1,014,000 | -31.4% | 32,026 | +0.5% | 0.01% | -30.8% |
| Q4 2020 | $1,478,000 | +38.3% | 31,852 | -1.9% | 0.01% | +18.2% |
| Q3 2020 | $1,069,000 | +60.8% | 32,459 | +33.9% | 0.01% | +22.2% |
| Q2 2020 | $665,000 | -11.8% | 24,241 | -3.7% | 0.01% | -30.8% |
| Q1 2020 | $754,000 | – | 25,182 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 11,826,299 | $130,562,000 | 4.09% |
| MPM BioImpact LLC | 1,200,000 | $13,248,000 | 3.68% |
| Finepoint Capital LP | 960,200 | $10,601,000 | 3.66% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 3,011 | $273,000,000 | 2.85% |
| Avoro Capital Advisors LLC | 9,220,000 | $101,789,000 | 2.01% |
| Long Focus Capital Management, LLC | 1,625,000 | $17,940,000 | 1.88% |
| 683 Capital Management, LLC | 2,000,000 | $22,080,000 | 1.56% |
| Parametrica Management Ltd | 115,870 | $1,268,000 | 1.38% |
| Boxer Capital, LLC | 1,935,133 | $21,364,000 | 1.35% |
| Soleus Capital Management, L.P. | 719,600 | $7,944,000 | 1.24% |